Archived Medical News Stories

RSSArchived Drug Trial News Stories - March 2010

Date Title Comments Rating
2010-03-31 Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer 0 5
2010-03-31 ViroPharma initiates Phase 2 clinical study to evaluate Cinryze 0 None
2010-03-31 DSMB for DIGNITY trial recommends Celsion continue enrollment 0 None
2010-03-31 ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC 0 None
2010-03-31 Investment report on Sunesis Pharmaceuticals 0 None
2010-03-31 SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference 0 3
2010-03-31 Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data 0 None
2010-03-31 PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic 0 None
2010-03-31 QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations 0 None
2010-03-31 YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387 0 None
2010-03-31 Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction 0 None
2010-03-30 FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine 0 1
2010-03-30 NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss 0 None
2010-03-30 CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN 0 None
2010-03-30 Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD 0 None
2010-03-30 GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer 0 None
2010-03-30 Trius Therapeutics' Phase 1 trial establishes safety and tolerability of IV torezolid phosphate for MRSA 0 None
2010-03-29 NexMed files IND with FDA for Phase II trial of PrevOnco for HCC 0 None
2010-03-29 Interim data comparing Cervista HPV HR to Hybrid Capture 2 presented at 4th Biennial Meeting of AOGIN 0 None
2010-03-29 Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced 0 None
2010-03-29 Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress 0 4
2010-03-29 Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD 0 None
2010-03-29 Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC 0 None
2010-03-29 Genta reports net loss of $11.7M for fourth-quarter 2009 0 None
2010-03-29 ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009 0 None
2010-03-26 Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy 0 None
2010-03-26 Avid, Cardinal Health partner to detect Alzheimer's disease in living patients 1 None
2010-03-26 Muscular dystrophy: $1M grant for study of erectile dysfunction drugs in improving muscle blood flow 0 None
2010-03-26 NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy 0 None
2010-03-26 Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV 0 None
2010-03-26 Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule 0 None
2010-03-26 Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced 0 None
2010-03-26 FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD 0 None
2010-03-26 Positive results from Stage A pivotal study of 2009 A/H1N1 VLP pandemic influenza vaccine 0 None
2010-03-26 Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX 0 None
2010-03-26 Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C 0 None
2010-03-26 Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial 0 None
2010-03-26 Aastrom Biosciences' RESTORE-CLI trial: Final patient treated 0 None
2010-03-26 DARA BioSciences announces the initiation of Phase I clinical study for DB959 0 None
2010-03-25 Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916 0 None
2010-03-25 Scott & White seeks breast cancer patients for Phase II clinical trial 0 None
2010-03-25 Biogen Idec and Elan begin comparative trial of MS treatments 0 5
2010-03-25 Clinic sites seek gay men to participate in HIV vaccine study 0 None
2010-03-25 Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference 0 None
2010-03-24 Shingles drug receives clearance for final stage of testing 0 None
2010-03-24 Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study 0 None
2010-03-23 Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery 0 None
2010-03-23 Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases 0 None
2010-03-23 Merck Serono, EMD Serono suspend global clinical development program for Stimuvax temporarily 0 None
2010-03-23 Inhibitex announces net loss of $4.7M for fourth-quarter 2009 0 None
2010-03-23 Aradigm reports net loss of $3.4M for fourth-quarter 2009 0 None
2010-03-23 Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands 0 None
2010-03-23 CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval 0 None
2010-03-23 Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years 0 None
2010-03-22 Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated 0 None
2010-03-22 Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine 0 None
2010-03-22 ChemoCentryx undertakes Phase II clinical trial of CCX140 0 None
2010-03-22 First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat 0 None
2010-03-22 Simcere Pharmaceutical completes Phase IV clinical study of Endostar 0 None
2010-03-22 Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1 0 None
2010-03-22 PharmAthene suspends work on SparVax research and development contract with BARDA 0 None
2010-03-22 Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate 0 None
2010-03-22 Phase II Topical Interferon Alpha-2b trial for AGW: Helix BioPharma achieves last-patient-out 0 None
2010-03-19 Major study shoots for personalized breast cancer drugs 0 5
2010-03-19 CPEX Pharmaceuticals' Phase 2a Nasulin trial fails, Arcadia Capital Advisors issues statement 0 None
2010-03-19 Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients 0 None
2010-03-19 A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter 0 None
2010-03-19 Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010 0 None
2010-03-19 FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched 0 None
2010-03-19 Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056 0 None
2010-03-19 ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation 0 None
2010-03-18 Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints 0 None
2010-03-18 Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series 0 None
2010-03-18 Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study 0 None
2010-03-18 Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD 0 None
2010-03-18 Findings from Study 305 evaluating the effect of Northera reported 0 None
2010-03-18 Agendia to participate in groundbreaking clinical trial for breast cancer 0 None
2010-03-18 Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin 0 None
2010-03-17 Nabi Biopharmaceuticals commences second Phase III study of NicVAX for treating nicotine addiction 0 None
2010-03-17 ONGLYZA-metformin combination: FDA accepts NDA for review 0 2
2010-03-17 Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC 0 None
2010-03-17 Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002 0 None
2010-03-17 Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar 0 None
2010-03-17 Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD 0 None
2010-03-17 Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint 0 None
2010-03-17 Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications 0 None
2010-03-17 Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC 0 None
2010-03-17 TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene 0 None
2010-03-17 Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution 0 None
2010-03-17 Booster shot appears to improve TB resistance in previously vaccinated adults 0 None
2010-03-17 Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting 0 None
2010-03-16 PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients 0 None
2010-03-16 Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients 1 2.5
2010-03-16 Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent 0 3
2010-03-16 Iverson Genetic Diagnostics to conduct WARFARIN clinical study 0 None
2010-03-16 Promedior raises $12M in Series C financing 0 None
2010-03-16 EXPLORE-Xa study: Betrixaban reduces CRNM bleeds compared to dose-adjusted warfarin 0 3
2010-03-16 Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint 0 None
2010-03-16 Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis 0 5
2010-03-16 Positive results from Phase IIa epilepsy study of ICA-105665 0 None
2010-03-15 Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development 0 None
2010-03-15 CytRx plans five Phase 2 clinical trials with oncology drug candidates 0 None
2010-03-15 YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR 0 None
2010-03-15 Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis 0 None
2010-03-15 Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study 0 None
2010-03-15 Data from ACCORD Lipid study: Abbott issues statement 0 None
2010-03-15 Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly 0 None
2010-03-15 Regadenoson drug is safe for heart transplant patients: Study 0 None
2010-03-15 XOMA 052 reduces adverse consequences that lead to development of congestive heart failure 0 None
2010-03-15 ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes 0 None
2010-03-12 XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients 0 5
2010-03-12 TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints 0 None
2010-03-12 Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009 0 None
2010-03-12 CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk 0 None
2010-03-12 Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010 0 None
2010-03-12 AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy 0 None
2010-03-12 Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints 0 None
2010-03-12 Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy 0 None
2010-03-12 Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC 0 None
2010-03-12 Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug 0 None
2010-03-12 Genentech announces topline results from Phase III trial of Avastin 0 None
2010-03-12 PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS 0 None
2010-03-12 Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL 0 None
2010-03-11 FDA provides guidance on Restanza clinical program in treatment of CABP 0 4.7
2010-03-11 Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45% 0 None
2010-03-11 Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study 0 None
2010-03-11 Evotec completes first-in-human Phase I study of EVT 103 for treatment-resistant depression 0 None
2010-03-11 Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage 0 None
2010-03-11 NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil 0 4
2010-03-11 Lithera announces positive results from Phase IIa clinical study of LIPO-102 0 None
2010-03-10 Positive results from Limerick BioPharma's LIM-0705 Phase 1a trial 0 None
2010-03-10 NeoPharm seeks Orphan Drug Designation for IL13-PE38QQR in treatment of IPF 0 None
2010-03-10 Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment 0 None
2010-03-10 Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009 0 None
2010-03-10 Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide 0 None
2010-03-10 AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B 0 None
2010-03-10 Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010 0 None
2010-03-10 Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program 0 None
2010-03-10 Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes 0 None
2010-03-10 Cellectar completes enrollment in (131)I-CLR1404 Phase I dosimetry trial for advanced solid malignancies 0 None
2010-03-09 Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV 0 None
2010-03-09 Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury 0 None
2010-03-09 Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK 0 None
2010-03-09 JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK 0 None
2010-03-09 Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray 0 None
2010-03-08 ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC 0 None
2010-03-08 Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009 0 None
2010-03-08 Rexahn Pharmaceuticals granted Japanese patent for Archexin 0 None
2010-03-08 Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer 0 None
2010-03-08 NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete 0 None
2010-03-08 Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC 0 None
2010-03-08 VIVUS granted three additional patents for Qnexa 0 None
2010-03-08 Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals 0 None
2010-03-08 DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test 0 None
2010-03-08 Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting 0 None
2010-03-06 Presentation of results from open-label extension study of Xenazine 0 None
2010-03-06 Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results 0 None
2010-03-05 LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting 0 None
2010-03-05 Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced 0 4
2010-03-05 Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients 0 5
2010-03-05 Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented 0 None
2010-03-04 BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine 0 3.2
2010-03-04 Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs 0 None
2010-03-04 Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue 0 None
2010-03-04 Belatacept drug can prevent graft rejection in kidney transplant recipients 0 None
2010-03-04 Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments 0 None
2010-03-04 Allergan, Bristol-Myers Squibb sign global exclusive license agreement for EHT/AGN 0001 0 None
2010-03-04 Endocyte's PRECEDENT study: DSMB recommends enrollment to continue 0 None
2010-03-04 Androxal Type C meeting: Repros Therapeutics receives FDA’s version of minutes 0 None
2010-03-04 Negative results from latrepirdine Phase III clinical trial: Alzheimer's Association disappointed 0 None
2010-03-04 Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA 0 None
2010-03-03 Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer 0 5
2010-03-03 AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement 0 None
2010-03-03 Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients 0 None
2010-03-03 FDA issues new draft guidance for Trius Therapeutics' proposed Phase 3 trial of torezolid phosphate 0 None
2010-03-03 Merck’s MF/F Phase III study data presented at AAAAI annual meeting 0 None
2010-03-03 Merck announces updated late-stage pipeline following its recent merger with Schering-Plough 0 5
2010-03-03 Phase III study results of Merck's allergy immunotherapy tablet 0 None
2010-03-02 Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB 0 None
2010-03-02 Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development 0 None
2010-03-02 Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial 0 None
2010-03-02 Archimedes Pharma raises GBP65 million in new funding 0 None
2010-03-02 IgPro20 protects PI patients against infection 0 None
2010-03-02 PTSD drug: Cannabis Science to file first application for FDA clinical trials 0 None
2010-03-02 Celsion to commence Phase II Study of ThermoDox and RFA for CRLM 0 None
2010-03-02 Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION 0 None
2010-03-01 Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment 0 None
2010-03-01 Synexus recruits 87% of agreed number of patients in major osteoporosis study within deadline 0 None
2010-03-01 [11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment 0 None


189 posts
27 raters